Their surface antigens, which include programmed cell death protein 1 (PD-1) and its ligand PD-L1, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the antigen-presenting cell integral membrane protein B7, provide substratum for the development of targeted immunotherapies for head-and-neck cancers directed towards correction of the tumor-associated B cell functionalities, [11,78,79,80]. The gene discussed is PDCD1; the disease is head and neck cancer.